Acurx is a no-revenue antibiotic developer with a Phase 3-ready CDI lead asset, a new recurrent-CDI pilot plan, repeated equity financing, and explicit going-concern pressure. The question is whether ibezapolstat gets financed into proof before dilution becomes the main story.
The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.
